Ethylene diamine tetramethylene phosphonic acid labeled with various β --emitting radiometals: Labeling optimization and animal biodistribution

Cancer Biotherapy and Radiopharmaceuticals

Volumn 26, Issue 2, 2011, Pages 159-164

  Sohaib, Muhammad ^a   Ahmad, Mushtaq ^b   Jehangir, Mustansar ^b   Perveen, Azra ^a  

^a PAKISTAN INSTITUTE OF ENGINEERING AND APPLIED SCIENCES   (Pakistan)

^b PAKISTAN INSTITUTE OF NUCLEAR SCIENCE AND TECHNOLOGY   (Pakistan)

Author keywords

bone marrow; bone metastasis; myelosuppression; radionuclide; radiopharmaceuticals

Indexed keywords

ETHYLENEDIAMINE TETRAKIS(METHYLENEPHOSPHONIC ACID); ETHYLENEDIAMINE TETRAKIS(METHYLENEPHOSPHONIC ACID) HOLMIUM HO 166; ETHYLENEDIAMINE TETRAKIS(METHYLENEPHOSPHONIC ACID) LUTETIUM LU 177; ETHYLENEDIAMINE TETRAKIS(METHYLENEPHOSPHONIC ACID) YTTRIUM Y 90; HOLMIUM; LEXIDRONAM SAMARIUM SM 153; LUTETIUM 177; SAMARIUM 153; UNCLASSIFIED DRUG; YTTRIUM 90;

ANIMAL EXPERIMENT; ARTICLE; BETA RADIATION; DRUG ACCUMULATION; DRUG DISTRIBUTION; ELECTRON RADIATION; ISOTOPE LABELING; MALE; NONHUMAN; PH; PRIORITY JOURNAL; RAT;

ANIMALS; BETA PARTICLES; BONE AND BONES; BONE MARROW; ISOTOPE LABELING; MALE; METALS, RARE EARTH; ORGANOMETALLIC COMPOUNDS; ORGANOPHOSPHORUS COMPOUNDS; PAIN; PALLIATIVE CARE; PHOSPHONIC ACIDS; RADIONUCLIDE IMAGING; RADIOPHARMACEUTICALS; RATS; RATS, SPRAGUE-DAWLEY; TISSUE DISTRIBUTION;

EID: 79955914764     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/cbr.2010.0846     Document Type: Article

References (20)

1. Bouchet LG, Bolch WE, Goddu SM, et al. Considerations in the selection of radiopharmaceuticals for palliation of bone pain from metastatic osseous lesions. J Nucl Med 2000; 41:682.
2. Serafini AN, Houston SJ, Resche I, et al. Palliation of pain associated with metastatic bone cancer using samarium-153 lexidronam: A double-blind placebo-controlled clinical trial. J Clin Oncol 1998;16:1574.
3. Turner JH, Claringbold PG, Berger JD, et al. 153Sm-EDTMP and melphalan chemoradiotherapy regimen for bone marrow ablation prior to marrow transplantation: An experimental model in the rat. Nucl Med Commun 1992;13:321.
4. Bartlett ML, Webb M, Durrant S, et al. Dosimetry and toxicity of quadramet for bone marrow ablation in multiple myeloma and other haematological malignancies. Eur J Nucl Med Mol Imaging 2002;29:1470.
5. Anderson PM, Wiseman GA, Dispenzieri A, et al. Highdose samarium-153 ethylene diamine tetramethylene phosphonate: Low toxicity of skeletal irradiation in patients with osteosarcoma and bone metastases. J Clin Oncol 2002; 20:189.
6. Maini CL, Bergomi S, Romano L, et al. 153Sm-EDTMP for bone pain palliation in skeletal metastases. Eur J Nucl Med Mol Imaging 2004;31:S171.
7. Turner JH, Claringbold PG, Manning LS, et al. Radiopharmaceutical therapy of 5T33 murine myeloma by sequential treatmentwith samarium-153 ethylenediaminetetramethylene phosphonate, melphalan, and bone marrow transplantation. J Natl Cancer Inst 1993;85:1508.
8. Louw WK, Dormehl IC, van Rensburg AJ, et al. Evaluation of samarium-153 and holmium-166-EDTMP in the normal baboon model. Nucl Med Biol 1996;23:935.
9. Chakraborty S, Das T, Unni PR, et al. 177Lu labelled polyaminophosphonates as potential agents for bone pain palliation. Nucl Med Commun 2002;23:67.
10. Rösch F, Herzog H, Plag C, et al. Radiation doses of yttrium- 90 citrate and yttrium-90 EDTMP as determined via analogous yttrium-86 complexes and positron emission tomography. Eur J Nucl Med 1996;23:958.
11. Ishfaq MM, Mushtaq A, Jawaid M. Experience on the neutron activation of natural/enriched Re, Sm, and Ho nuclides in a reactor for the production of radiotherapeutic radionuclides. Biol Trace Elem Res 1999;71-72:519.
12. Goeckeler WF, Edwards B, Volkert WA, et al. Skeletal localization of samarium-153 chelates: Potential therapeutic bone agents. J Nucl Med 1987;28:495.
13. Appelbaum FR, Brown PA, Sandmaier BM, et al. Specific marrow ablation before marrow transplantation using an aminophosphonic acid conjugate 166Ho-EDTMP. Blood 1992;80:1608.
14. Ernestova M, Jedináova7á- Křížová V, Vav̌ ura P. Potentiometric study of holmium complexes with EDTMP. Croat Chem Acta 2004;77:633.
15. Jarvis NV, Wagener JM, Jackson GE. Metal-ion speciation in blood plasma as a tool for elucidating the in vivo behavior of radiopharmaceuticals containing 153Sm and 166Ho. J Chem Soc Dalton Trans 1995;9:1411.
16. Chakraborty S, Das T, Sarma HD, et al. Comparative studies of 177Lu-EDTMP and 177Lu-DOTMP as potential agents for palliative radiotherapy of bone metastasis. Appl Radiat Isot 2008;66:1196.
17. Garnuszek P, Pawlak D, Licińska I, et al. Evaluation of a freeze-dried kit for EDTMP-based bone-seeking radiopharmaceuticals. Appl Radiat Isot 2003;58:481.
18. de Witt GC, May PM, Webb J, et al. Potentiometric and computer studies of yttrium-EDTMP. Inorg Chim Acta 1998; 275-276:37.
19. Turner JH, Claringbold PG, Berger JD, et al. 153Sm-EDTMP and melphalan chemoradiotherapy regimen for bone marrow ablation prior to marrow transplantation: An experimental model in the rat. Nucl Med Commun 1992;13:321.
20. Macfarlane DJ, Durrant S, Bartlett ML, et al. 153Sm EDTMP for bone marrow ablation prior to stem cell transplantation for haematological malignancies. Nucl Med Commun 2002; 23:1099.